Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenue:
Product sales, net	$ 4,416	$ 4,820	$ 8,316	$ 9,308
License fees and consulting revenue	98	71	696	166
Grant revenue	81	302	164	348
Total revenue	4,595	5,193	9,176	9,822
Costs and operating expenses:
Cost of product sales	4,137	4,834	6,976	8,976
Research and development expenses	17,597	8,645	44,005	15,391
Selling, general, and administrative expenses	13,632	4,567	23,431	8,904
Total costs and operating expenses	35,366	18,046	74,412	33,271
Operating loss	(30,771)	(12,853)	(65,236)	(23,449)
Interest expense	3,281	49	5,657	3
Unrealized loss on derivative liability	4,587		8,863
Loss before income tax expense (benefit)	(38,639)	(12,902)	(79,756)	(23,452)
Income tax expense (benefit)	29	(403)	(63)	(303)
Net loss	(38,668)	(12,499)	(79,693)	(23,149)
Less: net loss attributable to non-controlling interests	(43)	(78)	(80)	(110)
Net loss attributable to Athenex, Inc.	(38,625)	(12,421)	(79,613)	(23,039)
Unrealized (loss) gain on investment, net of income taxes	(37)	67	(34)	63
Foreign currency translation adjustment, net of income taxes	181	(393)	680	(427)
Comprehensive loss	$ (38,481)	$ (12,747)	$ (78,967)	$ (23,403)
Net loss per share attributable to Athenex, Inc. common stockholders, basic and diluted	$ (0.88)	$ (0.31)	$ (1.89)	$ (0.59)
Weighted-average shares used in computing net loss per share attributable to Athenex, Inc. common stockholders, basic and diluted	43,741,096	39,775,112	42,208,612	39,321,739